Barclays Forecasts Strong Price Appreciation for Envista (NYSE:NVST) Stock

Envista (NYSE:NVST) had its price objective increased by Barclays from $24.00 to $34.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price would indicate a potential upside of 14.79% from the company’s current price.

A number of other research analysts have also recently issued reports on NVST. Morgan Stanley set a $19.00 price objective on shares of Envista in a research note on Friday. Evercore reiterated an “outperform” rating and issued a $32.00 price target on shares of Envista in a research note on Friday. Zacks Research upgraded Envista from a “hold” rating to a “strong-buy” rating in a research report on Friday, February 6th. Evercore ISI set a $32.00 target price on Envista and gave the company an “outperform” rating in a research report on Friday. Finally, UBS Group boosted their target price on Envista from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $27.43.

Envista Stock Down 1.8%

Shares of NYSE NVST opened at $29.62 on Wednesday. Envista has a 52 week low of $14.22 and a 52 week high of $30.42. The stock’s fifty day moving average is $23.17 and its 200 day moving average is $21.37. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.04 and a current ratio of 2.38. The stock has a market capitalization of $4.87 billion, a P/E ratio of 105.96, a PEG ratio of 2.01 and a beta of 1.01.

Envista (NYSE:NVST) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. The firm had revenue of $750.60 million for the quarter, compared to the consensus estimate of $680.26 million. Envista had a net margin of 1.73% and a return on equity of 6.54%. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Sell-side analysts forecast that Envista will post 1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

Several institutional investors have recently added to or reduced their stakes in the business. Ariel Investments LLC grew its position in shares of Envista by 1.7% during the 2nd quarter. Ariel Investments LLC now owns 12,355,666 shares of the company’s stock worth $241,430,000 after buying an additional 210,921 shares during the period. Dimensional Fund Advisors LP boosted its stake in Envista by 4.0% during the third quarter. Dimensional Fund Advisors LP now owns 9,537,874 shares of the company’s stock worth $194,284,000 after acquiring an additional 367,363 shares in the last quarter. Franklin Resources Inc. grew its holdings in Envista by 16.7% in the second quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock worth $175,011,000 after purchasing an additional 1,284,767 shares during the period. Alliancebernstein L.P. increased its stake in Envista by 34.0% in the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after purchasing an additional 1,547,656 shares in the last quarter. Finally, Clarkston Capital Partners LLC raised its holdings in shares of Envista by 0.4% during the second quarter. Clarkston Capital Partners LLC now owns 4,703,330 shares of the company’s stock valued at $91,903,000 after purchasing an additional 16,583 shares during the period.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.